Trial Profile
A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2021
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary) ; Rotigotine
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Luye Pharma Group
- 31 Mar 2021 Status changed from recruiting to completed.
- 25 Feb 2019 Planned End Date changed from 25 Dec 2018 to 25 Apr 2019.
- 15 Nov 2018 New trial record